Physician profile
Ralph Highshaw
NPI 1386726453
$38,128.87
in general payments reported to CMS, 2019-2025
30 companies · $2,641 in 2025
The $2,641 reported for 2025 was more than what 85% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,648 · 2020: $26K · 2021: $6,598 · 2022: $19.66 · 2023: $583 · 2024: $1,033 · 2025: $2,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,083 · Education: $1,500 · Travel and Lodging: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,082.65 |
| Education | $1,500.00 |
| Travel and Lodging | $674.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $33,025.77 | 2020-2025 | |
| Boston Scientific Corporation | $2,148.96 | 2019-2025 | Ams 700, Lithovue, Lynx System |
| Procept Biorobotics Corporation | $907.38 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Medtronic USA, INC. | $346.83 | 2020 | |
| Myriad Genetic Laboratories, INC. | $219.55 | 2024-2025 | Prolaris |
| Medtronic, INC. | $159.59 | 2021-2025 | Interstim, Altaviva |
| Teleflex LLC | $144.21 | 2021-2025 | Barrigel |
| Janssen Biotech, INC. | $140.91 | 2019-2020 | |
| Travere Therapeutics, INC. | $135.79 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $113.77 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $91.68 | 2024 | Adstiladrin |
| Coloplast Corp | $91.25 | 2021-2025 | Titan |
| Smith+Nephew, INC. | $90.38 | 2024-2025 | Stravix |
| Baxter Healthcare | $86.76 | 2019 | |
| Allergan, INC. | $46.40 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $45.89 | 2024 | Illuccix |
| Abbvie INC. | $40.20 | 2019-2024 | |
| Neotract INC. | $38.65 | 2020 | |
| Tolmar, INC. | $35.47 | 2024 | |
| Blue Earth Diagnostics | $31.45 | 2025 | Posluma |
| Ambu INC. | $26.43 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.21 | 2024 | |
| Dendreon Pharmaceuticals LLC | $20.95 | 2021 | |
| Endo USA, INC. | $19.40 | 2025 | Xiaflex |
| Immunitybio, INC. | $19.32 | 2025 | |
| Davol INC. | $19.06 | 2024 | Arista Ah Flexitip |
| Myovant Sciences INC. | $18.51 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.06 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $13.44 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Highshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.